Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer-Reference-Cited by-同舟云学术

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer

Published:2011-01 Issue:2 Volume:47 Page:206-214
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fischer von Weikersthal Ludwig,Schalhorn Andreas,Stauch Martina,Quietzsch Detlef,Maubach Peter A.,Lambertz Helmut,Oruzio Daniel,Schlag Rudolf,Weigang-Köhler Karin,Vehling-Kaiser Ute,Schulze Manfred,Truckenbrodt Juergen,Goebeler Mariele,Mittermüller Johann,Bosse Daniel,Szukics Borika,Grundeis Marc,Zwingers Thomas,Giessen Clemens,Heinemann Volker

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial;Douillard;Lancet,2000

2. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group;Saltz;N Engl J Med,2000

3. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer;De Gramont;J Clin Oncol,2000

4. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin;Zeghari-Squalli;Clin Cancer Res,1999

5. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics;Wasserman;J Clin Oncol,1999

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

2. Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials;BMC Cancer;2024-07-24

3. Impact of Primary Tumor Sidedness on Prognosis and Anti-EGFR Antibody Efficacy in BRAF-Mutant Metastatic Colorectal Cancer: A Pooled Analysis of AIO Studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;2024

4. The heterogeneity effect of surveillance intervals on progression free survival;Journal of Applied Statistics;2022-11-14

5. A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials;American Journal of Clinical Oncology;2022-07-15